Suchergebnisse - "Matsubara, Nobuaki"

PubPharm (242)

1

PD-1 inhibition with retifanlimab and/or arginase inhibition with INCB001158 in Japanese patients with solid tumors : A phase I study

enthalten in: Cancer medicine | 2024

von Kuboki, Y. | Koyama, T. | Matsubara, N. | +12

2

A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2024

von Dorff, T. | Horvath, L. | Autio, K. | +25

3

TAS0313 plus Pembrolizumab for Post-Chemotherapy Immune Checkpoint Inhibitor-Naïve Locally Advanced or Metastatic Urothelial Carcinoma

enthalten in: Molecular cancer therapeutics | 2024

von Nishiyama, H. | Yonese, J. | Kawahara, T. | +10

4

Pembrolizumab with or Without Lenvatinib as First-line Therapy for Patients with Advanced Urothelial Carcinoma (LEAP-011) : A Phase 3, Randomized, Double-Blind Trial

enthalten in: European urology | 2024

von Matsubara, N. | de Wit, R. | Balar, A. | +18

5

TALAPRO-3 clinical trial protocol : phase III study of talazoparib plus enzalutamide in metastatic castration-sensitive prostate cancer

enthalten in: Future oncology (London, England) | 2024

von Agarwal, N. | Saad, F. | Azad, A. | +8

6

Safety and pharmacokinetics of imaradenant (AZD4635) in Japanese patients with advanced solid malignancies : a phase I, open-label study

enthalten in: Cancer chemotherapy and pharmacology | 2024

von Matsubara, N. | Kusuhara, S. | Yamamoto, N. | +7

7

Health-related Quality of Life in Patients with Previously Treated Advanced Urothelial Carcinoma from EV-301 : A Phase 3 Trial of Enfortumab Vedotin Versus Chemotherapy

enthalten in: European urology | 2024

von Rosenberg, J. | Mamtani, R. | Sonpavde, G. | +28

8

Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in BRCA1 and/or BRCA2 in the PROfound Trial

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2024

von Mateo, J. | de Bono, J. | Fizazi, K. | +20

9

Publisher Correction : First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial

enthalten in: Nature medicine | 2024

von Fizazi, K. | Azad, A. | Matsubara, N. | +18

ErratumFor: Nat Med. 2024 Jan;30(1):257-264. - PMID 38049622

10

Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer : Results from Dose Exploration in a First-in-Human Study

enthalten in: Cancer discovery | 2024

von Kelly, W. | Danila, D. | Lin, C. | +18

CommentIn: Cancer Discov. 2024 Jan 12;14(1):20-22. - PMID 38213299

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[25]